Roche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new cancer treatments. The agreement will incorporate Molecular Partners ...
WHO's EUL process is based on a thorough evaluation of quality, safety, and performance data, ensuring compliance with ...
The new test is compatible with Roche's cobas 5800, 6800, and 8800 molecular diagnostic analysers, which are widely used in hospitals and other clinical settings, without any need for upgrades.
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
The base business in this division grew 8%, driven by demand for immunodiagnostic, pathology and molecular solutions products. Roche’s shares have risen 8.2% year to date compared with the ...
PredicineCAREâ„¢ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing ...
The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback